Apollo Hospitals Enterprise Ltd Q3 FY2024 Concall Summary

Key Takeaways

• Healthcare Services margin reset underway: Margins dipped to 23.8% on seasonal mix and talent investment, but management targets a 200 bps improvement over the next few quarters.
• HealthCo breaks even ahead of schedule: The digital health and pharmacy distribution arm posted a positive EBITDA of ₹2 crore, one quarter earlier than guided, validating the omnichannel thesis.
• Apollo 24/7 GMV guidance trimmed, but growth path intact: FY24 GMV is now expected at ₹2,750–2,800 crore (vs. the earlier ₹3,000 crore), with 60–70% growth still pencilled in for next year and a breakeven commitment in 6–8 quarters.
• Bed expansion plan formalized: The group will add 2,000 beds over 4 years at a cost of ₹3,000 crore, with new hospitals in Pune, Hyderabad, and Kolkata plus a Bangalore brownfield expansion going live in FY25.
• What to watch next quarter: Whether the 200 bps margin recovery begins to materialize, the pace of 24/7 GMV rebound after the festive dip, and any concrete update on the digital therapeutics and insurance monetization launches promised for Q1–Q2.

Healthcare Services: Margins, Occupancy & Expansion

• Margin headwinds were seasonal and structural: The 23.8% margin reflected a reduced share of elective and surgical revenue during the holiday and festive season, plus an incremental ₹100 crore spend on clinical talent across the system that has yet to be fully optimized.
• Talent investment is a volume play: The ₹100 crore in new doctor expenses is aimed at moving system-wide occupancy from 66% to 70% and growing clinical programs: oncology grew 17% and urology 14%, directly attributable to new hires.
• Occupancy held at 66% despite headwinds: This was achieved even as average length of stay declined and institutional volumes were deliberately calibrated; retail and institutional business, which makes up 80–85% of the mix, grew 7.5% in volume year-on-year.
• New bed EBITDA losses expected to be minimal: The Bangalore brownfield expansion sits adjacent to an existing hospital, which should limit the drag, and most new beds come onstream only in Q4 of next fiscal. Management declined to quantify the expected EBITDA loss.
• Structural demand tailwinds are intact: More people have access to private insurance, and demand is increasing across metros, Tier 1 and Tier 2 cities. Management expects very strong growth in upcoming quarters.

Krishnan Akhileswaran: "Internally, we would like to believe that there is an opportunity to increase the margins by at least 200 basis points over the next few quarters. And that's our internal way of looking at it."

Apollo HealthCo & Omnichannel Pharmacy

• HealthCo EBITDA turned positive at ₹2 crore: The break-even arrived one quarter ahead of guidance, driven by pharmacy margin improvement as infrastructure costs normalized and discounting was reined in.
• Offline pharmacy grew 19.4% over nine months on fewer store additions; management expects to return to a normal store-opening cadence and sustain 20–22% growth, with further profitability headroom from cost rationalization and maturing stores.
• Omnichannel pharmacy is on track to hit ₹1,000 crore in revenue at a 6% EBITDA margin (pre-AS 116).
• HealthCo EBITDA trajectory endorsed: Per an analyst's math, the business could reach ₹800–1,000 crore in EBITDA over the next couple of years; management agreed with a ~20% year-on-year growth assumption.

Apollo 24/7: GMV Reset & Path to Breakeven

• FY24 GMV guidance trimmed to ₹2,750–2,800 crore from the earlier ₹3,000 crore, still a 75–80% increase over FY23. Q3 saw a seasonal dip from holidays and festivals, but January and Q4 numbers have returned to growth.
• Next year's growth pegged at 60–70% and breakeven is committed within 6–8 quarters. The path depends on three new verticals whose entire earnings flow straight to EBITDA: digital therapeutics, insurance distribution, and app monetization.
• Insurance distribution launched in January and app monetization is expected to begin in Q1, with a subscription-led digital therapeutics module rolling out across Q1 and Q2. New customer additions of 0.2 crore will take time to transact, so the impact starts showing from the current quarter.
• Management declined to provide breakeven math: When asked whether existing services alone could get to breakeven, management confirmed the new verticals are necessary but did not share specific revenue or margin contribution figures.
• Fundraise optionality is open-ended: The business is described as self-sustaining, but management is "open to the idea" of raising cash at some point, with no specific answer on IPO or fundraise plans.

Sanjiv Gupta: "I think these three particular offerings, which is digital therapeutic, insurance and app monetization, these are the three segments, we could give you a better margin line. In fact, the entire earnings that you earn out of these three verticals would go back or flow back down to EBITDA."

AHLL: Specialty Formats & Diagnostics

• Specialty format growth was muted as many new centers were commissioned in Q3 and Q4, and the transition from older to newer centers weighed on year-to-date numbers. The Chennai cyclone also delayed business recovery in Q3.
• Volume growth was concentrated in outpatient footfalls while Cradles and Spectra centers moved to new locations without enough rooms, constraining inpatient conversion. Management is confident of returning to double-digit growth from the next financial year.
• Diagnostics growth is entirely volume-led in an industry where 10–12% growth is mostly price-driven with single-digit volume growth. Apollo's expansion, new centers, and lab investments are driving the volume, and the outlook is for 20% growth in the coming year.

Strategic Updates & Regulatory

• CAR-T cell therapy milestone: Apollo became the first private hospital group in India to complete the CAR-T cell program, providing access to a Made-in-India CAR-T cell therapy.
• New facilities commissioned: A 50-bed SAIL Hospital in Rourkela was operationalized (250-bed capacity), 100 beds were added in Indore via brownfield expansion, and Delhi's Indraprastha hospital is adding 50 beds plus a new neurology department.
• Gurugram facility is 100% owned by AHEL and is expected to increase international patient revenue given its location and clinical portfolio.
• Kidney racket article had no negative finding: Management stated the group was fully compliant with the Board and all government regulations.
• 100% cashless insurance mandate is neutral to positive: Apollo's insurance business is already entirely cashless, so no negative impact is expected; the mandate may even shorten the receivables period.

Suneeta Reddy: "We believe that this comprehensive platform, with opportunities for improving our offering on consumer experience and lifetime value, offers us a competitive moat and headroom for accelerated growth."

Guidance & Commitments

Key Metrics